APC Anti-CTLA4 antibody [BNI3] (ab210253)
Key features and details
- APC Mouse monoclonal [BNI3] to CTLA4
- Suitable for: Flow Cyt
- Reacts with: Human
- Conjugation: APC. Ex: 645nm, Em: 660nm
- Isotype: IgG2a
Overview
-
Product name
APC Anti-CTLA4 antibody [BNI3]
See all CTLA4 primary antibodies -
Description
APC Mouse monoclonal [BNI3] to CTLA4 -
Host species
Mouse -
Conjugation
APC. Ex: 645nm, Em: 660nm -
Tested applications
Suitable for: Flow Cytmore details -
Species reactivity
Reacts with: Human
Predicted to work with: Baboon, Cynomolgus monkey, Rhesus monkey -
Immunogen
The details of the immunogen for this antibody are not available.
-
Positive control
- Human peripheral blood lymphocytes.
-
General notes
This is a neutralizing antibody.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C. Store In the Dark. -
Storage buffer
pH: 7.20
Preservative: 0.09% Sodium azide
Constituents: 0.12% Monobasic dihydrogen sodium phosphate, 0.1% Gelatin, 0.87% Sodium chloride -
Concentration information loading...
-
Purity
Affinity purified -
Purification notes
Purified from tissue culture supernatant and conjugated under optimal conditions, with unreacted dye removed from the preparation. -
Clonality
Monoclonal -
Clone number
BNI3 -
Isotype
IgG2a -
Light chain type
kappa -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
-
Recombinant Protein
Applications
Our Abpromise guarantee covers the use of ab210253 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
Flow Cyt | Use 5µl for 105-8 cells. in 100 μl volume. |
Target
-
Function
Inhibitory receptor acting as a major negative regulator of T-cell responses. The affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory coreceptor CD28. -
Tissue specificity
Widely expressed with highest levels in lymphoid tissues. Detected in activated T-cells where expression levels are 30- to 50-fold less than CD28, the stimulatory coreceptor, on the cell surface following activation. -
Involvement in disease
Genetic variation in CTLA4 influences susceptibility to systemic lupus erythematosus (SLE) [MIM:152700]. SLE is a chronic, inflammatory and often febrile multisystemic disorder of connective tissue. It affects principally the skin, joints, kidneys and serosal membranes. SLE is thought to represent a failure of the regulatory mechanisms of the autoimmune system.
Note=Genetic variations in CTLA4 may influence susceptibility to Graves disease, an autoimmune disorder associated with overactivity of the thyroid gland and hyperthyroidism.
Genetic variation in CTLA4 is the cause of susceptibility to diabetes mellitus insulin-dependent type 12 (IDDM12) [MIM:601388]. A multifactorial disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy. Clinical fetaures are polydipsia, polyphagia and polyuria which result from hyperglycemia-induced osmotic diuresis and secondary thirst. These derangements result in long-term complications that affect the eyes, kidneys, nerves, and blood vessels.
Genetic variation in CTLA4 is the cause of susceptibility to celiac disease type 3 (CELIAC3) [MIM:609755]. It is a multifactorial disorder of the small intestine that is influenced by both environmental and genetic factors. It is characterized by malabsorption resulting from inflammatory injury to the mucosa of the small intestine after the ingestion of wheat gluten or related rye and barley proteins. In its classic form, celiac disease is characterized in children by malabsorption and failure to thrive. -
Sequence similarities
Contains 1 Ig-like V-type (immunoglobulin-like) domain. -
Post-translational
modificationsN-glycosylation is important for dimerization.
Phosphorylation at Tyr-201 prevents binding to the AP-2 adapter complex, blocks endocytosis, and leads to retention of CTLA4 on the cell surface. -
Cellular localization
Cell membrane. Exists primarily an intracellular antigen whose surface expression is tightly regulated by restricted trafficking to the cell surface and rapid internalisation and. - Information by UniProt
-
Database links
- Entrez Gene: 1493 Human
- Omim: 123890 Human
- SwissProt: P16410 Human
- Unigene: 247824 Human
-
Alternative names
- ALPS5 antibody
- CD 152 antibody
- CD antibody
see all
Images
-
Flow Cytometrical analysis of Human peripheral blood lymphocytes labeling CTLA4 using 5 μL (0.125 μg) ab210253 (solid line) or 0.125 μg Allophycocyanin Mouse IgG2a isotype control (dashed line). Right panel: CD4+, CD45RO+ cells. Left pane: CD4+, CD45RO- cells.
Datasheets and documents
References (0)
ab210253 has not yet been referenced specifically in any publications.